Research Article

Use of Antiasthmatic Drugs during Pregnancy after the First Trimester and Maternal and Neonatal Outcomes

Table 4

Preterm birth, low birth weight, and small-for-gestational age (SGA) in women who got prescriptions for antiasthmatic drugs prior to pregnancy week 37. Odds ratios (OR) with 95% confidence intervals (95% CI) adjusted for year of delivery, maternal age, parity, smoking, and BMI. Bold text marks statistical significance.

OutcomeAntiasthmatic drug usedNumber with outcomeTotal numberOR95% CI

Preterm birthAny54297421.080.98–1.18
Inhaled short-acting β-2 agonist38567411.100.99–1.22
Inhaled long-acting β-2 agonist9815711.231.001.51
Inhaled corticosteroid32959091.080.96–1.21
Montelukast202161.821.152.87

Low birth weightAny36897281.121.001.24
Montelukast132151.720.94–2.88#

SGAAny29297271.371.211.54
Inhaled short-acting β-2 agonist19467311.311.131.51
Inhaled long-acting β-2 agonist6815361.921.592.45
Inhaled corticosteroid12541181.391.161.67
Montelukast102151.770.853.25

Among 323054 infants in the population with known gestational duration, 15850 were preterm, among 322770 with known birth weight, 10481 were low birth weight, among 322599 infants with known gestational duration, known birth weight, and sex, and 7183 were SGA.
#RR as observed/expected number with exact 95% CI.